Advanced Search

Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 36.87 -5.32% -2.07
APLS closed down 5.32 percent on Friday, February 21, 2020, on 70 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down
Historical APLS trend table...
Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Older EOD signals for APLS ...
View Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
APLS Chart by TradingView
Basic chart:

Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Autoimmune And Inflammatory Diseases Chronic Obstructive Pulmonary Disease Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Feb 6 CEO council reveals innovation center location, plans international summit
Jan 23 The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Jan 16 The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Jan 15 Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
Jan 13 Apellis Pharmaceuticals' stock offering closes $50M higher than expected
Jan 13 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
Jan 13 Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019
Jan 10 Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of Biopharma
Jan 9 Apellis Pharmaceuticals is planning to raise $350M — here's how
Jan 9 Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH Patients
See more APLS news...

Indicators

Indicator Value
52 Week High 45.04
52 Week Low 13.8
Average Volume 1,533,674
200-Day Moving Average 28.61
50-Day Moving Average 36.83
20-Day Moving Average 41.69
10-Day Moving Average 41.25
Average True Range 2.02
ADX 28.98
+DI 17.39
-DI 28.25
Chandelier Exit (Long, 3 ATRs ) 38.97
Chandelier Exit (Short, 3 ATRs ) 42.79
Upper Bollinger Band 45.12
Lower Bollinger Band 38.25
Percent B (%b) -0.2
BandWidth 16.48
MACD Line 0.46
MACD Signal Line 1.44
MACD Histogram -0.9853
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.86
Resistance 3 (R3) 41.25 40.32 40.20
Resistance 2 (R2) 40.32 39.30 40.12 39.97
Resistance 1 (R1) 38.59 38.67 38.13 38.20 39.75
Pivot Point 37.66 37.66 37.42 37.46 37.66
Support 1 (S1) 35.93 36.64 35.47 35.54 33.99
Support 2 (S2) 35.00 36.01 34.80 33.77
Support 3 (S3) 33.27 35.00 33.55
Support 4 (S4) 32.88